Rhenman & Partners Asset Management Ab Cytokinetics Inc Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Cytokinetics Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 180,500 shares of CYTK stock, worth $8.51 Million. This represents 0.79% of its overall portfolio holdings.
Number of Shares
180,500
Previous 197,515
8.61%
Holding current value
$8.51 Million
Previous $10.7 Million
10.94%
% of portfolio
0.79%
Previous 1.06%
Shares
12 transactions
Others Institutions Holding CYTK
# of Institutions
409Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$692 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$555 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$457 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$367 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$305 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.44B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...